VA
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | 2025 | 15 | 14 | |||
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | 2024 | 96 | 114 | |||
LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | 2023 | 104 | 42 | |||
Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | 2022 | 75 | 99 | |||
Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites | Clinical Pharmacokinetics | 2018 | 719 | 723 | |||
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers | Basic & clinical pharmacology & toxicology | 2013 | 650 | 408 | |||
The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro | British journal of pharmacology | 2012 | 578 | 0 | |||
Inhibiteurs des récepteurs plaquettaires P2Y12 à l'ADP: importance du métabolisme et influence des interactions médicamenteuses sur leurs paramètres pharmacocinétiques | 2012 | 1,104 | 2,174 | ||||
Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients | Metabolism, clinical and experimental | 2011 | 679 | 0 | |||
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability | Current drug metabolism | 2010 | 659 | 0 |